Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, Gazyva, and Xeloda; osteoporosis, including Actemra, Edirol, and Bonviva; renal diseases consist of Mircera and Oxarol; and neurology/other diseases comprise Hemlibra, CellCept, and Enspryng. It has various development product candidates in the areas of oncology, bone and joint diseases, autoimmune diseases, renal diseases, neurology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Tokyo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.

Chugai Pharmaceutical Co., Ltd.

DAIKYO specializes in the manufacturing of pharmaceutical and medical packages, consistently providing innovative products since its establishment in 1954.

DAIKYO

Chugai Pharmaceutical Co., Ltd. is involved in the sales management, development, and regulatory affairs of pharmaceutical products across various regions including Europe, North America, and Asia. The company also engages in clinical development and investment activities.

Metric
Company Name	Chugai Pharmaceutical Co., Ltd.	DAIKYO
Symbol	4.52K
MSH ID	JP:CO:CHUGAI-PHARM	JP:DAIKYOSEIKO
Market	STOCKS	PRIVATE
Sector	Healthcare	Consumer Goods
Industry	Drug Manufacturers - General	Medical Devices & Packaging
Country	JP	JP
Stage
Employee Count	7.60K
Website	chugai-pharm.co.jp	daikyoseiko.jp
LinkedIn
Founders

Metric
Market Cap	69.75B
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	7.41B
Revenue (LTM)
Revenue (NTM)
Gross Profit	4.66B
EBITDA	2.95B
Operating Income	2.74B
Net Income	2.17B
EPS	1.32
Diluted EPS	1.32
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.69
Operating Profit Margin	0.44
EBITDA Margin	0.40
Net Profit Margin	0.33
Return on Equity	0.22
Return on Assets	0.17
Return on Capital Employed	0.28

4519

JP:CO:CHUGAI-PHARM

CHUGAI PHARMACEUTICAL CO., LTD.

Last Close

7,255.00

14/02 06:30

Market Cap

10.45T

Beta: -

Volume Today

2.07M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	25.03
P/B Ratio	5.49
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	11.20
EV Multiple	25.82

Metric
Days Sales Outstanding	90.72
Days Payables Outstanding	76.79
Days Inventory Outstanding	301.52
Operating Cycle	410.68
Cash Conversion Cycle	323.67
Asset Turnover	0.58

Metric
Operating Cash Flow	2.74B
Free Cash Flow	2.25B
Cash Flow to Debt
Operating Cash Flow/Sales	0.37
Free Cash Flow Yield	0.02

Metric
Cash & Equivalents	3.06B
Accounts Receivable
Inventory	1.82B
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio	4.76
Quick Ratio	4.37

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.14
SG&A to Revenue	0.01